Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos, a drug discovery company, has signed new collaboration agreements with Merck Serono, a division of Merck KGaA, Darmstadt, Germany. Total value of the contracts for Galapagos is E1.1 million over one year.
Subscribe to our email newsletter
Galapagos’s service division BioFocus DPI will provide SoftFocus compounds for use in Merck Serono’s drug discovery programs. In a separate agreement, BioFocus DPI will perform medicinal chemistry services on an undisclosed Merck Serono program; this represents an extension of a long running collaboration which was last expanded in 2005.
Onno Stolpe, CEO of Galapagos, said: “BioFocus DPI has a long relationship with Merck Serono in medicinal chemistry, which we are pleased to extend again this year. The purchase of BioFocus DPI’s SoftFocus libraries underscores our ability to grow business with clients.”